Stock Ideas 
News Letter Reviews Dr. Huang's FDA Report Reviews
News Letter Reviews Dr. Huang's FDA Report Reviews 
Market Watch
|
By Jeff Clark Ah, memories. It seems like it was just yesterday when we were turning the calendar to 2001. The Internet bubble had burst. The country was heading into a recession. And the dollar was collapsing as the Federal Reserve Board lowered interest rates to head off an economic catastrophe. |
|
| More... |
Most Popular
Login Form
| Dr. Huang's FDA Report Reviews |
| Friday, 01 January 2010 | ||||||
|
At the time, it was trading for just $2 a share. There was nothing exciting about the company. It didn't have a new miracle drug waiting for FDA approval... a research break-through... or any upcoming partnerships. To most people, it was a loser. But when Dr. Huang analyzed both the scientific and financial details of the company, he discovered that this little-known biotech firm receives royalty payments on two drugs that together generate $350 million in sales per year. He immediately recommended the stock to his FDA Report readers, writing: "They are looking to return cash to shareholders via a special dividend or share repurchase." Sure enough, in just seven months, the company did exactly what Dr. Huang said it would... and his readers saw a 98% gain. But that's just one example of what Dr. Huang uncovers in The FDA Report... Truth is, he has one of the best track records of any advisory letter in S&A history: In 2009 alone, Dr. Huang has shown his readers 12 double-digit winners and 4 triple-digit winners. Consider... Last fall, Dr. Huang predicted that a company called Intermune (ITMN) would see positive results for its Phase III trial of pirfenidone, a lung drug. His readers had the opportunity to make 88% gains in 14 days... and 105% gains in just 7 weeks, with the drug maker Dendreon (DNDN). Soon after, Dr. Huang uncovered a regulatory "loophole" in the FDA's drug approval process. Readers who followed his advice saw 49% gains in 3 months on ViroPharma (VPHM). He also predicted that the FDA would not require new trials from Indevus (IDEV), the "male menopause" drug maker. Readers saw a 74% gain in 6 months. And April 2009, Dr. Huang closed out a trade on Genentech Inc. (DNA) after correctly predicting a successful buyout. FDA Report subscribers saw a nearly 100% gain in just 4 months. As you can see, Dr. Huang has been very successful... ...But what really matters is how subscribers do with his research Dr. Huang's trading recommendations have outperformed our most optimistic expectations... "The FDA Report is the only newsletter that has consistently made me money in the past year. I've made 100% on IDEV, 160% on SPPI, 25% on DYAX, and 40% on DNDN." R.R., Chesapeake, VA "It's been fun following your picks... I made 70% in 4 weeks with Intermune!" P.S., Lancaster, PA In short, when it comes to the medical sector, Dr. Huang has found a way to make money with just about every situation you can imagine... drug approvals... buyouts... even failed drugs. Let me show you what I mean... 83% in 60 DAYS You remember the story about ImClone (IMCL), one of billionaire investor Carl Icahn's most successful biotech endeavors? Well, Dr. Huang was all over it... In the space of just 4 weeks, FDA Report readers had the chance to make 59% on ImClone... Some subscribers made even more on Dr. Huang's buyout predictions... 83% in 60 days on Alpharma 99% in 6 months on Wyeth 88% in 14 days on Intermune FDA Report subscribers have made a fortune... "Dr. Huang, great call on Genentech... I pocketed $22,000" J.R., Stanford, Ca "It's been a bit over a year now and I have to say that the results have been nothing short of spectacular, especially compared to what the overall market has done over the past year... I made 190% with IDEV and 200% with SPPI." H.C., Chelmsford, MA And that's not all... Dr. Huang has even found a way to make money on FAILED drugs! 80% return even when drugs fail I'm sure I don't have to tell you that one of the most profitable things you can do in America is develop a new drug to treat a debilitating disease. The rewards are simply staggering... For example, drug companies can charge about $20,000 per year for a single successful drug. It's no wonder blockbuster drug makers go from penny stocks to household names. But what most investors don't know is that you can make a fortune every time a new drug FAILS. And because new drugs fail 80% of the time... well... you could make an absolute fortune on these situations, often overnight. In fact, it's a secret Dr. Huang has used personally, in his own trading account, to predictably and consistently make a killing in the pharmaceutical industry: For example, not too long ago, a company called Introgen (INGN) began touting their new cancer drug, Advexin. Shares of Introgen topped $3 as mainstream investors piled in. But when he investigated the company... and the science behind the drug... Dr. Huang realized that the drug could never work. When it failed at the FDA, Dr. Huang made 80% as the stock crashed. And then... Several months ago, a company called Electro-Optical Sciences (MELA) began developing a device to screen for skin cancer. Anticipation of the trial results pushed the stock to almost $10... but Dr. Huang knew the device would never make it past the FDA. Sure enough, he made a quick 60% profit. These opportunities are everywhere. You just have to know where to find them. After spending years working in the biotech sector alongside the scientists and doctors behind clinical drug trials, Dr. Huang knows exactly what to look for. In July 2009, for example, Dr. Huang knew that the stem-cell drug produced by Osiris Therapeutics (OSIR) would FAIL its Phase III trials at the FDA this month. By recommending a unique play to take advantage of this situation, Dr. Huang has already shown his readers a 59% gain. Believe me, nothing quite like Dr. Huang's FDA Report advisory newsletter exists anywhere in the financial world. Whether it's a new drug approval... failed drug trial... buyout... even a stock trade like the New Jersey-based company Dr. Huang is recommending now – his readers have consistently seen huge returns. As FDA subscriber Joseph Menth writes: What are Dr. Huang's credentials? He might just be the smartest person I've ever met in my career. He graduated high school 3 years early. Then, at the age of 19, he landed a venture-capital job, securing private seed money for a Vancouver-based firm called Helios Bioinformatics Inc. He then spent 5 years at one of the top medical schools in America, Johns Hopkins. He earned his PhD in Cellular & Molecular Medicine (CMM) under the mentorship of the 2003 Nobel Laureate in Chemistry. Not to mention... he's fluent in 3 languages... and is attaining fluency in a fourth... "I have been giving FDA teasers to a friend at work, but up till last week he hadn't made a move on any S&A newsletter. But when I crowed to him about closing an FDA pick for 413%, I had his attention. When I added that the only other FDA pick I had closed this year did 198%, he asked for a link and signed up that day." Of course, the situation Dr. Huang is most excited about right now is the NJ-based biotech company I've been telling you about... As I mentioned, we don't know the exact date this small company might pay the special dividend. But the Board of Directors – chaired by billionaire Carl Icahn's right-hand man – is deciding what the company will do with the proceeds of the sale, as I write... How much could investors expect to receive? Well, with Carl Icahn behind this deal, Dr. Huang believes it could be between 60% and 100%. In short, it could be the biggest dividend in stock market history. If you get in alongside this billionaire investor today, you could possibly double your money in a single day. But before I tell you how to get started... let me make something clear: The FDA Report is not for everyone If you're only interested in taking a "buy-and-hold" approach to your investing, The FDA Report may not be right for you. It's not meant for beginners. Dr. Huang uses a trading strategy, focusing only on opportunities that offer abnormally quick returns... in a matter of weeks, sometimes, even days. So if you've never bought an option or shorted a stock before, and never intend to, then I suggest you look elsewhere. That said, every play Dr. Huang recommends is clearly outlined and explained in a simple, step-by-step manner, so you understand exactly what to do. FDA Report subscriber Dan Quartin agrees: "Even a layperson can understand what's going on. Thanks for the great picks and insightful commentary." So how much does The FDA Report cost? Well, in the past, we've charged $5,000 a year for similar research. But, beginning right now and ending shortly, we're going to make it much easier for you to give this research letter a try... We're offering The FDA Report at a HUGE discount. If you get in before this offer expires... you can receive one full year of The FDA Report for just $1,200. Considering the hours of work and the depth of analysis Dr. Huang does every month, $1,200 is an absolute bargain. Even better, we'll give you 90 days to decide whether or not Dr. Huang's research is right for you. If it's not... of if you're unhappy for any reason... no problem. Just let us know and we'll give you a refund, minus a small 10% processing fee. Personally, I think getting The FDA Report for $1,200 a year is an absolute steal, considering that just one of his recommendations could help you make 10 times that amount. The truth is, there are very few people in the investment world who understand enough about science and enough about finance to see the potential of these situations. Dr. Huang is one of those few people. And it gives him (and his readers) an incredible advantage in the markets... As his readers are saying: "I made 186% gains on Indevus. The profit was more than enough to pay for another year of FDA. I'm expecting even better returns from FDA in the coming year." H.C., Spartansburg, SC "I have made some quite spectacular gains... the Spectrum trade alone paid for my subscription cost!" M.M., Cherry Hill, NJ "I bought QLTI and made more than 100% in less than 2 months. This more than pays for the subscription. Most (if not all) your stock picks have been home runs. Remarkable!" B.J., Bethesda, MD The fact is – you could easily make back the entire subscription cost by getting in on the New Jersey-based biotech company I've told you about today. Remember, you could double your money, overnight. You'll find full details of the play in Dr. Huang's newest report: My Top Trade for 2010. Here's what you'll receive as a new FDA Report member... What you'll receive as a new subscriber When you sign up to receive The S&A FDA Report, you'll immediately begin receiving Dr. Huang's monthly trading research reports... the kind of picks that have returned: 105% in 2 months... 142% in 2 months... 88% in 14 days... (In fact, just days ago, he closed a play for a 95% gain in just 2 months.) In the next 5 minutes, you'll receive access to... Special Report: My top trade for 2010. This members-only report details what Dr. Huang believes is the absolute best and safest investment opportunity of 2010. It's a situation in which you could have the opportunity to safely pocket a special dividend of 60% to 100%... with very little risk. And because the details of the special dividend have yet to be announced, you could make a lot of money by joining Carl Icahn on this deal. FDA Report Trading Primer: This special report will explain everything you need to know about Dr. Huang's trading strategies. Read it right away, before you review anything else. You'll learn the full details behind Dr. Huang's approach to making money in the medical sector, including many interesting techniques I didn't have time to explain in this letter. FDA Report Monthly Issues: Every month, Dr. Huang will send you a new report – detailing the most recent trading opportunity he's found. Depending on what he uncovers, Dr. Huang will often recommend up to 2 to 4 new plays per issue. FDA Report Trading Alerts: Throughout the month, Dr. Huang will keep you posted by email on every single play he recommends, as necessary. Use these alerts to optimize your gains and see even bigger returns with Dr. Huang's recommended portfolio. To get started, Subscribe Now Sincerely, George Rayburn Publisher, Stansberry & Associates December 2009 P.S. Don't forget... you can get the FDA Report for just $1,200 – a huge discount from the regular price. But this offer is available for a limited time. See the order form for more details. Subscribe Now
|
||||||
| < Prev | Next > |
|---|
